The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Abstract
CONTEXT: Adverse drug reactions are a significant cause of morbidity and mortality. Although many adverse drug reactions are considered nonpreventable, recent developments suggest these reactions may be avoided through individualization of drug therapies based on genetic information, an application known as pharmacogenomics. OBJECTIVE: To evaluate the potential role of pharmacogenomics in reducing the incidence of adverse drug reactions. DATA SOURCES: MEDLINE English-language only searches for adverse drug reaction studies published between January 1995 and June 2000 and review articles of variant alleles of drug-metabolizing enzymes published between January 1997 and August 2000. We also used online resources, texts, and expert opinion. STUDY SELECTION: Detailed inclusion criteria were used to select studies. We included 18 of 333 adverse drug reaction studies and 22 of 61 variant allele review articles. DATA EXTRACTION: All the investigators reviewed and coded articles using standardized abstracting forms. DATA SYNTHESIS: We identified 27 drugs frequently cited in adverse drug reaction studies. Among these drugs, 59% are metabolized by at least 1 enzyme with a variant allele known to cause poor metabolism. Conversely, only 7% to 22% of randomly selected drugs are known to be metabolized by enzymes with this genetic variability (range, P =.006-P<.001). CONCLUSIONS: Our results suggest that drug therapy based on individuals' genetic makeups may result in a clinically important reduction in adverse outcomes. Our findings serve as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse reactions and on the resulting clinical, societal, and economic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
To Err Is Human: Building a Safer Health System
(2000) · National Academies Press eBooks · doi:10.17226/9728 · Cited by 14,044
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Arky, R. A. (1994) · Cited by 2,632
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention
Bates, D. W. (1995) · JAMA · doi:10.1001/jama.1995.03530010043033 · Cited by 2,127
Incidence and Types of Adverse Events and Negligent Care in Utah and Colorado
Thomas, E. J., Studdert, D. M., Burstin, H. R., Orav, E. J., Zeena, T., Williams, E. J., Howard, K. M., Weiler, P. C., & Brennan, T. A. (2000) · Medical Care · doi:10.1097/00005650-200003000-00003 · Cited by 1,673
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Classen, D. C. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540280039031 · Cited by 1,134
Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis
Petitti, D. B. (1999) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195133646.001.0001 · Cited by 925
Implications of the Human Genome Project for Medical Science
Collins, F. S. (2001) · JAMA · doi:10.1001/jama.285.5.540 · Cited by 838
Medical and Ethical Consequences of the Human Genome Project
Collins, F. S. (1991) · The Journal of Clinical Ethics · doi:10.1086/jce199102411 · Cited by 666
Computerized Surveillance of Adverse Drug Events in Hospital Patients
Classen, D. C. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470200059035 · Cited by 639
Pharmacogenetics and adverse drug reactions
Meyer, U. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03167-6 · Cited by 602
MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISM
Meyer, U. A., & Zanger, U. M. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.269 · Cited by 549
Adverse Drug Events In High Risk Older Outpatients
Hanlon, J. T., Schmader, K. E., Koronkowski, M. J., Weinberger, M., Landsman, P. B., Samsa, G. P., & Lewis, I. K. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb02964.x · Cited by 443
McLeod, H., Krynetski, E., Relling, M., & Evans, W. (2000) · Leukemia · doi:10.1038/sj.leu.2401723 · Cited by 437
Will Genetics Revolutionize Medicine?
Holtzman, N. A., & Marteau, T. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007133430213 · Cited by 408
Taube, J., Halsall, D., & Baglin, T. (2000) · Blood · doi:10.1182/blood.v96.5.1816 · Cited by 392
Wormhoudt, L. W., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Critical Reviews in Toxicology · doi:10.1080/10408449991349186 · Cited by 302
Hasler, J. A., Estabrook, R., Murray, M., Pikuleva, I., Waterman, M., Capdevila, J., Holla, V., Helvig, C., Falck, J. R., Farrell, G., et al. (1999) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(99)00005-9 · Cited by 267
Pharmacogenomics: The promise of personalized medicine
Mancinelli, L., Cronin, M., & Sadée, W. (2000) · AAPS PharmSci · doi:10.1208/ps020104 · Cited by 267
Wandel, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108506 · Cited by 246
Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness
Weinstein, M. C., Goldie, S. J., Losina, E., Cohen, C. J., Baxter, J. D., Zhang, H., Kimmel, A. D., & Freedberg, K. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-6-200103200-00008 · Cited by 235
Pharmacogenetics of Sulfotransferase
Nagata, K., & Yamazoe, Y. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.159 · Cited by 215
Safe health care: are we up to it?
Leape, L. L. (2000) · BMJ · doi:10.1136/bmj.320.7237.725 · Cited by 199
Adverse Drug Events in Hospitalized Patients
Classen, D. C., Pestotnik, S. L., Evans, R. S., Lloyd, J. F., & Burke, J. P. (1998) · Survey of Anesthesiology · doi:10.1097/00132586-199806000-00009 · Cited by 170
Basile, V. S., Özdemir, V, Masellis, M., Walker, M. L., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Alva, G., Kalow, W., Macciardi, F. M., et al. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000736 · Cited by 168
Assessing the cost-effectiveness of pharmacogenomics
Veenstra, D. L., Higashi, M. K., & Phillips, K. A. (2000) · AAPS PharmSci · doi:10.1208/ps020329 · Cited by 160
Self-citationDrug‐Related Hospital Admissions
Nelson, K. M., & Talbert, R. L. (1996) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb03658.x · Cited by 158
Genetics and Public Health in the 21st Century
(2000) · doi:10.1093/acprof:oso/9780195128307.001.0001 · Cited by 157
Molecular genetics of the human cytochrome P450 monooxygenase superfamily
Smith, G. C., Stubbins, M. J., Harries, L. W., & Wolf, C. R. (1998) · Xenobiotica · doi:10.1080/004982598238868 · Cited by 146
Adverse Drug Events in Elderly Patients Receiving Home Health Services following Hospital Discharge
Gray, S. L., Mahoney, J., & Blough, D. K. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.19036 · Cited by 141
Krynetski, E. Y., & Evans, W. E. (1999) · Pharmaceutical Research · doi:10.1023/a:1011909315614 · Cited by 136
Medication-Related Visits to the Emergency Department: A Prospective Study
Tafreshi, M. J., Melby, M. J., Kaback, K. R., & Nord, T. C. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.19062 · Cited by 134
Cytochrome P450 Enzyme System: Genetic Polymorphisms and Impact on Clinical Pharmacology
van der Weide, J., & Steijns, L. S. W. (1999) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329903600604 · Cited by 129
Error in Medicine: What Have We Learned?
Bates, D. W., & Gawande, A. A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00025 · Cited by 124
Adverse Drug Events in Hospitalized Elderly
Gray, S. L., Sager, M. A., Lestico, M. R., & Jalaluddin, M. (1998) · The Journals of Gerontology Series A · doi:10.1093/gerona/53a.1.m59 · Cited by 121
Frequency of Hospitalization after Exposure to Known Drug‐Drug Interactions in a Medicaid Population
Hamilton, R. A., Briceland, L. L., & Andritz, M. H. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03942.x · Cited by 119
Nebert, D. W., Ingelman‐Sundberg, M., & Daly, A. K. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101931 · Cited by 107
Masimirembwa, C. M., & Hasler, J. A. (1997) · Brain Research Bulletin · doi:10.1016/s0361-9230(97)00307-9 · Cited by 96
Pharmacogenetics of antidepressants: clinical aspects
Bertilsson, I.-L., Dahl, M. L., & Tybring, G. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb05954.x · Cited by 96
Burchell, B., & Coughtrie, M. W. H. (1997) · Environmental Health Perspectives · doi:10.1289/ehp.97105s4739 · Cited by 94
Probable Adverse Drug Reactions in a Rural Geriatric Nursing Home Population: A Four‐Year Study
Cooper, J. W. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb02439.x · Cited by 93
Medication misadventures resulting in emergency department visits at and HMO medical center
Schneitman-McIntire, O., Farnen, T. A., Gordon, N. P., Chan, J., & Toy, W. A. (1996) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/53.12.1416 · Cited by 87
Pharmacogenomics — Teaching Old Drugs New Tricks
Weinstein, J. N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431910 · Cited by 65
Polymorphic Cytochromes P450 and Drugs Used in Psychiatry
Coutts, R. T., & Urichuk, L. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006945715127 · Cited by 65
Adverse drug reactions in hospitalized patients: A critique of a meta-analysis.
Kvasz, M., Allen, I., Mj, G., Ey, R., Estok, R. P., Olkin, I., & Ross, S. D. (2000) · PubMed · Cited by 55
Characteristics Associated with Ability to Prevent Adverse Drug Reactions in Hospitalized Patients
Seeger, J. D., Kong, S. X., & Schumock, G. T. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03149.x · Cited by 40
Incidence of adverse drug reactions in adult medical inpatients.
Bowman, L., Carlstedt, B. C., & Black, C. D. (1994) · The Canadian Journal of Hospital Pharmacy · Cited by 38
Public Health Genetics: An Emerging Interdisciplinary Field for the Post-Genomic Era
Omenn, G. S. (2000) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.21.1.1 · Cited by 36
Should HER2 status be routinely measured for all breast cancer patients?
Ravdin, P. M. (1999) · PubMed · Cited by 35
HIV-1 Drug Resistance Genotyping: A Review of Clinical and Economic Issues
Chaix-Couturier, C., Holtzer, C. D., Phillips, K. A., Durand‐Zaleski, I., & Stansell, J. (2000) · PharmacoEconomics · doi:10.2165/00019053-200018050-00002 · Cited by 26
Self-citationThe Interface of Genetics and Public Health: Research and Educational Challenges
Austin, M. A., Peyser, P. A., & Khoury, M. J. (2000) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.21.1.81 · Cited by 26
Vermes, A., Guchelaar, H., & Koopmans, R. P. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90031-1 · Cited by 15
Adverse drug reactions in a state psychiatric hospital.
Vd, W., & Sanchez, C. (1995) · PubMed · Cited by 1
Cited by
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Clinical importance of the cytochromes P450
Nebert, D. W., & Russell, D. W. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11203-7 · Cited by 1,414
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
(2007) · PubMed · Cited by 953
Subgroup analysis in randomised controlled trials: importance, indications, and interpretation
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17709-5 · Cited by 942
Metadata
- Authors
- Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-11-14
- Volume
- 286
- Issue
- 18
- Pages
- 2270
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1996323553
- Cited by
- 705
- References
- 56
- FWCI
- 38.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.